Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Dexcom (DXCM) EPS (Weighted Average and Diluted) (2016 - 2026)

Dexcom has reported EPS (Weighted Average and Diluted) over the past 14 years, most recently at $0.51 for Q1 2026.

  • Quarterly EPS (Weighted Average and Diluted) rose 88.89% to $0.51 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.33 through Mar 2026, up 73.88% year-over-year, with the annual reading at $2.09 for FY2025, 47.18% up from the prior year.
  • EPS (Weighted Average and Diluted) was $0.51 for Q1 2026 at Dexcom, down from $0.67 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $0.7 in Q3 2025 and troughed at $0.12 in Q2 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is $0.34 (2024), against an average of $0.36.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 2300.0% in 2022 against a maximum downside of 58.93% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.22 in 2022, then surged by 177.27% to $0.61 in 2023, then plummeted by 37.7% to $0.38 in 2024, then skyrocketed by 76.32% to $0.67 in 2025, then dropped by 23.88% to $0.51 in 2026.
  • Per Business Quant, the three most recent readings for DXCM's EPS (Weighted Average and Diluted) are $0.51 (Q1 2026), $0.67 (Q4 2025), and $0.7 (Q3 2025).